HRP20182183T1 - Liječenje hematoloških maligniteta sa anti-cxcr4 antitijelom - Google Patents

Liječenje hematoloških maligniteta sa anti-cxcr4 antitijelom

Info

Publication number
HRP20182183T1
HRP20182183T1 HRP20182183TT HRP20182183T HRP20182183T1 HR P20182183 T1 HRP20182183 T1 HR P20182183T1 HR P20182183T T HRP20182183T T HR P20182183TT HR P20182183 T HRP20182183 T HR P20182183T HR P20182183 T1 HRP20182183 T1 HR P20182183T1
Authority
HR
Croatia
Prior art keywords
malignity
hematological
treatment
cxcr4 antibody
cxcr4
Prior art date
Application number
HRP20182183TT
Other languages
English (en)
Croatian (hr)
Inventor
Michelle R. Kuhne
Chin Pan
Josephine M. Cardarelli
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20182183T1 publication Critical patent/HRP20182183T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20182183TT 2011-11-09 2012-11-09 Liječenje hematoloških maligniteta sa anti-cxcr4 antitijelom HRP20182183T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161557815P 2011-11-09 2011-11-09
US201161569113P 2011-12-09 2011-12-09
EP12787343.8A EP2776032B1 (en) 2011-11-09 2012-11-09 Treatment of hematologic malignancies with an anti-cxcr4 antibody
PCT/US2012/064395 WO2013071068A2 (en) 2011-11-09 2012-11-09 Treatment of hematologic malignancies with an anti-cxcr4 antibody

Publications (1)

Publication Number Publication Date
HRP20182183T1 true HRP20182183T1 (hr) 2019-02-22

Family

ID=47179025

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20182183TT HRP20182183T1 (hr) 2011-11-09 2012-11-09 Liječenje hematoloških maligniteta sa anti-cxcr4 antitijelom

Country Status (24)

Country Link
US (2) US10428151B2 (enExample)
EP (1) EP2776032B1 (enExample)
JP (1) JP6541350B2 (enExample)
KR (1) KR102024957B1 (enExample)
CN (1) CN104039320B (enExample)
AU (1) AU2012335553B2 (enExample)
BR (1) BR112014011144A2 (enExample)
CA (1) CA2855155A1 (enExample)
CY (1) CY1121331T1 (enExample)
DK (1) DK2776032T3 (enExample)
EA (1) EA026153B1 (enExample)
ES (1) ES2705001T3 (enExample)
HR (1) HRP20182183T1 (enExample)
HU (1) HUE043001T2 (enExample)
IL (1) IL232517B (enExample)
LT (1) LT2776032T (enExample)
MX (1) MX357100B (enExample)
PL (1) PL2776032T3 (enExample)
PT (1) PT2776032T (enExample)
RS (1) RS58102B1 (enExample)
SG (1) SG11201401386XA (enExample)
SI (1) SI2776032T1 (enExample)
SM (1) SMT201900026T1 (enExample)
WO (1) WO2013071068A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2486941B1 (en) * 2006-10-02 2017-03-15 E. R. Squibb & Sons, L.L.C. Human antibodies that bind CXCR4 and uses thereof
CA2840687C (en) 2011-07-01 2020-04-28 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
CA2920377A1 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
ES2742079T3 (es) 2013-11-06 2020-02-13 Bristol Myers Squibb Co Tratamiento de macroglobulinemia de Waldenström asociada a C1013G/CXCR4 con un anticuerpo anti-CXCR4
WO2015085075A1 (en) 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
CN113072644A (zh) 2013-12-17 2021-07-06 埃姆医疗有限公司 抵抗骨髓增生障碍或淋巴组织增生障碍的手段和方法
US10066014B2 (en) * 2014-02-06 2018-09-04 Yeda Research And Development Co. Ltd. Anti CD84 antibodies, compositions comprising same and uses thereof
AU2014383868A1 (en) * 2014-02-19 2016-09-08 MicroConstants China Inc, Disabled Disabled Disabled Chemokine receptor antagonist and its combinational therapy
SG10202111844VA (en) * 2015-01-09 2021-12-30 Adalta Ltd Cxcr4 binding molecules
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
EP3307778A1 (en) 2015-06-12 2018-04-18 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
CA2999756A1 (en) * 2015-09-24 2017-03-30 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
AU2016352910A1 (en) * 2015-11-09 2018-05-31 The General Hospital Corporation D.B.A Massachusetts General Hospital Unit dose formulations for use as an anti-fugetactic agent
BR112018016924A2 (pt) * 2016-02-23 2019-01-02 Biolinerx Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
JP2019518006A (ja) 2016-04-29 2019-06-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ
LT3458053T (lt) 2016-05-20 2022-02-25 Biohaven Pharmaceutical Holding Company Ltd. Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui
US20190175557A1 (en) * 2016-06-16 2019-06-13 Centre National De La Recherche Scientifique Compounds useful for decreasing interferon level
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
CN110234352A (zh) * 2017-01-31 2019-09-13 Msm蛋白质技术公司 抗cxcr4抗体
KR20200090982A (ko) * 2017-02-21 2020-07-29 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
IL269026B2 (en) 2017-03-31 2024-12-01 Bristol Myers Squibb Co Anti-pd-1 antibodies for treating tumors in high tumor mutational burden (tmb) patients
KR20200064132A (ko) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2019113456A1 (en) * 2017-12-08 2019-06-13 The Medical College Of Wisconsin, Inc. Chemokine variants as immune stimulants
CN112513079A (zh) * 2018-03-13 2021-03-16 拉巴斯大学医院生物医学研究基金会 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体
BR112020018539A2 (pt) 2018-03-23 2020-12-29 Bristol-Myers Squibb Company Anticorpos contra mica e/ou micb e usos dos mesmos
KR102825164B1 (ko) 2018-03-27 2025-06-26 브리스톨-마이어스 스큅 컴퍼니 자외선 신호를 사용한 단백질 농도의 실시간 모니터링
KR20200139724A (ko) 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
US20220220430A1 (en) 2019-05-23 2022-07-14 Bristol-Myers Squibb Company Methods of monitoring cell culture media
KR20220098732A (ko) 2019-10-08 2022-07-12 다나-파버 캔서 인스티튜트 인크. 요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
JP2025509274A (ja) 2022-03-09 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー 治療用タンパク質の一過性発現
JP2026504180A (ja) * 2023-01-30 2026-02-03 カイマブ・リミテッド 抗体
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
CN119119196B (zh) * 2024-08-01 2025-09-09 青岛大学 一种基于Motixafortide-喜树碱缀合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JP3367581B2 (ja) 1993-10-14 2003-01-14 小野薬品工業株式会社 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
EP1660654B1 (en) 2003-09-04 2011-11-09 Medarex, Inc. Expression vector
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
MX2008010999A (es) 2006-02-28 2008-09-08 Pharma Mar Sa Tratamientos anti-tumor mejorados.
EP2486941B1 (en) * 2006-10-02 2017-03-15 E. R. Squibb & Sons, L.L.C. Human antibodies that bind CXCR4 and uses thereof
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
KR20100133012A (ko) * 2008-05-14 2010-12-20 일라이 릴리 앤드 캄파니 항-ｃｘｃｒ4 항체
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
BRPI1006189A2 (pt) 2009-03-12 2020-08-18 Genentech Inc uso de uma combinação terapêutica, formulação farmacêutica, artigo de manufatura, produto, método para determinar compostos a serem utilizados em combinação para o tratamento de uma malignidade hematopoiética e método para selecionar compostos a serem utilizados em combinação para o tratamento de câncer
AR076590A1 (es) * 2009-05-19 2011-06-22 Vivia Biotech Sl Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos
MX2013002051A (es) 2010-08-20 2013-06-28 Cerulean Pharma Inc Particulas, composiciones y conjugados de peptido terapeutico-polimero y metodos relacionados.

Also Published As

Publication number Publication date
PT2776032T (pt) 2019-01-21
HUE043001T2 (hu) 2019-07-29
EA026153B1 (ru) 2017-03-31
SG11201401386XA (en) 2014-10-30
EP2776032B1 (en) 2018-10-17
ES2705001T3 (es) 2019-03-21
MX357100B (es) 2018-06-26
PL2776032T3 (pl) 2019-03-29
BR112014011144A2 (pt) 2017-05-16
JP2014533279A (ja) 2014-12-11
DK2776032T3 (en) 2019-02-04
MX2014005267A (es) 2014-07-28
CN104039320B (zh) 2019-10-15
CA2855155A1 (en) 2013-05-16
KR102024957B1 (ko) 2019-09-24
AU2012335553A1 (en) 2014-07-03
AU2012335553B2 (en) 2017-09-21
JP6541350B2 (ja) 2019-07-10
RS58102B1 (sr) 2019-02-28
SMT201900026T1 (it) 2019-05-10
IL232517A0 (en) 2014-06-30
US20200231683A1 (en) 2020-07-23
EP2776032A2 (en) 2014-09-17
LT2776032T (lt) 2018-12-10
EA201490957A1 (ru) 2014-08-29
CY1121331T1 (el) 2020-05-29
WO2013071068A3 (en) 2013-07-18
US10428151B2 (en) 2019-10-01
IL232517B (en) 2018-05-31
CN104039320A (zh) 2014-09-10
SI2776032T1 (sl) 2018-12-31
WO2013071068A2 (en) 2013-05-16
US20140322208A1 (en) 2014-10-30
KR20140093945A (ko) 2014-07-29

Similar Documents

Publication Publication Date Title
HRP20182183T1 (hr) Liječenje hematoloških maligniteta sa anti-cxcr4 antitijelom
HUS2300021I1 (hu) Anti-IL-36R antitestek
CO6811812A2 (es) Anticuerpo anti-b7-h3
CR20140127A (es) Anticuerpo anti-abtcr
HRP20181690T1 (hr) Varijante protutijela fc
EP2772298A4 (en) DRY
HRP20160484T1 (hr) Životinje koje izražavaju antitijela sa zajedničkim lakim lancem
EP2786485A4 (en) GUITAR AMP
EP2743171A4 (en) LIQUID NATURAL GAS VEHICLES
CO6890075A2 (es) Alcoholimetro calibrable
PL2663506T3 (pl) Zamknięcie
DK2705886T3 (da) Filtermekanisme
EP2744740A4 (en) BOOM STRUCTURE
EP2726839A4 (en) SAMPLERS
EP2703255A4 (en) CROSSMEMBER
LT2742068T (lt) Nauji antikūnai prieš fosforilcholiną
CO6841994A2 (es) Anticuerpos
EP2798329A4 (en) Sampling device
EP2741082A4 (en) SAMPLERS
DK2607881T3 (da) Koncentrationsapparat
DE112012004581A5 (de) Geruchsverschluss
UA22849S (uk) Гітара
UA22599S (uk) Корок
UA22598S (uk) Корок
UA22600S (uk) Корок